Showing results (261-270 of 277) with videos related to
Sort By:
Pageof 28
The New England Journal of Medicine|September 21, 2020
KRAS<sup>G12C</sup> Inhibition with Sotorasib in Advanced Solid TumorsDavid S Hong, Marwan G Fakih, John H Strickler, et al.The Journal of Clinical Investigation|May 20, 2009
Predicting drug susceptibility of non-small cell lung cancers based on genetic lesionsMartin L Sos, Kathrin Michel, Thomas Zander, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2026
A Phase 2 Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2Brandon M Huffman, Miklos Diossy, Matthew B Yurgelun, et al.Cancer Research|May 20, 2016
The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and CisplatinYifan Wang, Andrea J Bernhardy, Cristina Cruz, et al.Nature Cancer|April 26, 2021
EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancerKatherine L Morel, Anjali V Sheahan, Deborah L Burkhart, et al.The New England Journal of Medicine|July 30, 2015
Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell TumorWilliam D Tap, Zev A Wainberg, Stephen P Anthony, et al.Biorxiv : the Preprint Server for Biology|April 3, 2026
AI-Enhanced Adaptive Virtual Screening Platform Enabling Exploration of 69 Billion Molecules Discovers Structurally Validated FSP1 InhibitorsDomiziana Cecchini, AkshatKumar Nigam, Ming Tang, et al.Cancer Discovery|April 30, 2021
<i>FGFR2</i> Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in CholangiocarcinomaJames M Cleary, Srivatsan Raghavan, Qibiao Wu, et al.JCI Insight|November 25, 2016
Institutional implementation of clinical tumor profiling on an unselected cancer populationLynette M Sholl, Khanh Do, Priyanka Shivdasani, et al.Nature|February 14, 2019
Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancersDavid M Hyman, Sarina A Piha-Paul, Helen Won, et al.Pageof 28